Literature DB >> 9354565

Angiogenesis in the pathobiology and treatment of vascular and malignant diseases.

D S Winlaw1.   

Abstract

Cardiovascular disease and cancer account for the majority of adult disease in the developed world. This review focuses on current concepts in the study of angiogenesis (new vessel formation) as related to these conditions and highlights the role of vascular endothelial growth factor. Developments in therapeutic angiogenesis have raised the possibility that pharmacologic or gene-directed interventions, based on the ability of vascular endothelial growth factor to promote new vessel formation, may soon gain clinical application for the treatment of occlusive vascular disease. Similarly, the future treatment of malignant disease is likely to involve antiangiogenic agents that, in preliminary animal work, have demonstrated an efficacy that is not limited by adverse affects. Aside from these potential applications, current investigations have enhanced our understanding of mechanisms involved in the development of atherosclerotic and malignant disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9354565     DOI: 10.1016/s0003-4975(97)00716-9

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  Abnormalities in the recirculation phase of contrast agent bolus passage in cerebral gliomas: comparison with relative blood volume and tumor grade.

Authors:  Alan Jackson; Andrea Kassner; Deborah Annesley-Williams; Helen Reid; Xiau-Ping Zhu; Kah-Loh Li
Journal:  AJNR Am J Neuroradiol       Date:  2002-01       Impact factor: 3.825

2.  Expression of MMP-2 correlates with increased angiogenesis in CNS metastasis of lung carcinoma.

Authors:  Mumtaz V Rojiani; Janeen Alidina; Nicole Esposito; Amyn M Rojiani
Journal:  Int J Clin Exp Pathol       Date:  2010-10-16

3.  Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas.

Authors:  Qingguo Li; Daorong Wang; Jing Li; Ping Chen
Journal:  BMC Cancer       Date:  2011-06-27       Impact factor: 4.430

4.  Surface modification of TPGS-b-(PCL-ran-PGA) nanoparticles with polyethyleneimine as a co-delivery system of TRAIL and endostatin for cervical cancer gene therapy.

Authors:  Yi Zheng; Hongbo Chen; Xiaowei Zeng; Zhigang Liu; Xiaojun Xiao; Yongqiang Zhu; Dayong Gu; Lin Mei
Journal:  Nanoscale Res Lett       Date:  2013-04-09       Impact factor: 4.703

5.  Co-delivery of docetaxel and endostatin by a biodegradable nanoparticle for the synergistic treatment of cervical cancer.

Authors:  Bo Qiu; Minghui Ji; Xiaosong Song; Yongqiang Zhu; Zhongyuan Wang; Xudong Zhang; Shu Wu; Hongbo Chen; Lin Mei; Yi Zheng
Journal:  Nanoscale Res Lett       Date:  2012-12-06       Impact factor: 4.703

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.